India's Aurobindo Pharma Ltd. (524804.BY) said Monday it has received tentative approval from the U.S. Food and Drug Administration to manufacture and sell generic combination drug emtricitabine/tenofovir disproxil fumarate tablets.

Aurobindo has received the approval for the tablets in 200-milligram and 300-mg doses, it said in a filing to the Bombay Stock Exchange.

The tablets, which are used for the treatment of HIV-1 infection in adults, are the generic equivalent of Gilead Sciences Inc.'s (GILD) truvada, the company said.

-By Ameya Karve; Dow Jones Newswires; +91-22-22884212-18; ameyaanil.karve@dowjones.com